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Annexin A1 (ANXA1) down-regulation is an early and frequent event in the development of head 
and neck squamous cell carcinomas (HNSCC). In an attempt to identify the underlying mechanisms 
of reduced ANXA1 protein expression, this study investigated ANXA1 mRNA expression in HNSCC 
specimens by both in situ hybridization and RT-qPCR. Results showed a perfect concordance between 
the pattern of ANXA1 mRNA and protein detected by immunofluorescence in tumors, precancerous 
lesions and normal epithelia, reflecting that ANXA1 down-regulation occurs at transcriptional level. 
We also found that both miR-196a and miR-196b levels inversely correlated with ANXA1 mRNA levels 
in paired HNSCC tissue samples and patient-matched normal mucosa. In addition, endogenous levels 
of ANXA1 mRNA and protein were consistently and significantly down-regulated upon miR-196a and 
miR-196b over-expression in various HNSCC-derived cell lines. The direct interaction of both mature 
miR-196a and miR-196b was further confirmed by transfection with Anxa1 3′UTR constructs. Combined 
bioinformatics and functional analysis of ANXA1 promoter activity contributed to identify key regions 
and potential mediators of ANXA1 transcriptional control. This study unveils that, in addition to miR-
196a, miR-196b also directly targets ANXA1 in HNSCC.
Annexin A1 (ANXA1, also known as lipocortin 1 and calpactin II) is a pleiotropic 37 kDa protein member of the 
annexin superfamily with roles in vesicular trafficking and the maintenance of membrane-cytoskeletal integrity1. 
ANXA1 is considered a primary mediator of the anti-inflammatory, immunosuppressive actions of glucocorti-
coids2 and current attention has focused on its roles in membrane remodeling and cell behavior associated with 
regulatory signaling via the Formyl Peptide Receptor3 and oncogenesis4. These studies point to a major regulatory 
role for ANXA1 in cell-growth regulation and differentiation, neutrophil migration, CNS responses to cytokines, 
neuroendocrine secretion and apoptosis. The protein can be found in alternatively spliced isoforms, as proteolytic 
fragments of its bioactive N-terminus and as a heterotetramer with S100A11, localized to the nucleus, cytoplasm, 
membrane or extracellular matrix. It is a principal substrate for epidermal and hepatic growth factor (EGF and 
HGF) receptor tyrosine kinases and protein kinase C5, 6. These phosphorylation events target the PI3 kinase and 
ERK MAP kinase glucocorticoid signaling pathways to regulate cell proliferation, differentiation and apopto-
sis7. ANXA1 and other annexins are frequently deregulated in many cancers. ANXA1 overexpression has been 
reported in gastric8, pancreatic and hepatocellular carcinoma9 but it is markedly down-regulated in breast10, 11, 
prostate12, esophageal13 and head and neck squamous cell carcinomas14. The contrasting patterns of ANXA1 
expression in different tumors types is just one of the enigmas in deciphering the underlying regulatory mecha-
nisms and phenotypic specificity of ANXA1.
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It is now well established that ANXA1 down-regulation can be detected at the protein level in early stage 
tumorigenesis of HNSCC tissue specimens and visual microscopic evidence confirms that this is significantly 
correlated with advanced disease stage, lymph node metastasis and poor tissue differentiation14. More recently, 
the marked reduction of ANXA1 expression in epithelial dysplasia and strong positive expression in differenti-
ated layers of normal epithelia corresponded to inverse changes in levels of miR-196a under both conditions15–18.
Little is known about the underlying mechanisms responsible for the loss of ANXA1 expression in this type 
of cancer. Plausible mechanisms include genomic deletions, regulatory or coding mutations of the ANXA1 gene, 
epigenetic silencing by promoter hypermethylation, miRNA-mediated repression, alteration of one or more pro-
teins that regulate ANXA1 transcription such as IL-6, alterations in post-translational processing of the protein by 
proteolysis or phosphorylation, and defects of intracellular transport or protein localization that lead to reduced 
intracellular levels of ANXA1.
In an attempt to identify the cause of reduced ANXA1 protein expression in HNSCC, this study determined 
ANXA1 mRNA expression levels in HNSCC tissue specimens by both RT-qPCR and in situ hybridization. Since the 
ANXA1 3′UTR is a potential target of various microRNAs (15, 19 – miRBase, 20 – TargetScan) we focused on its 
documented regulatory relationship with the miR-196 family. These are noncoding RNAs derived from loci in the 
homeobox (HOX) gene clusters21 in human chromosomes 17q21.32 (MIR196A1), 12q13.13 (MIR196A2) and 7p15.2 
(MIR196B), among which the mature microRNAs miR-196a1 and a2 are identical and miR-196b differs by one 
nucleotide. As individual microRNAs can regulate multiple genes17, 18 including those encoding transcription factors, 
we also investigated the potential contribution of transcriptional control by analysis of ANXA1 promoter activity.
Results
Down-regulation of ANXA1 expression in HNSCC occurs at transcriptional level. We have previ-
ously reported that ANXA1 protein expression is frequently down-regulated in HNSCC tissue specimens, while 
highly expressed in the differentiated layers of normal epithelium14. ANXA1 expression at the mRNA level was 
assessed by in situ hybridization to investigate the possible underlying mechanisms of ANXA1 down-regulation 
in HNSCC. As shown in Fig. 1, the patterns of ANXA1 mRNA and protein expression (Fig. 2) perfectly matched. 
Strong ANXA1 mRNA expression was detected in the differentiated layers of normal epithelia while absent in 
basal and suprabasal cells (Fig. 1A). In situ hybridization confirmed the loss of ANXA1 mRNA expression in dys-
plastic epithelia (Fig. 1B) compared to normal adjacent epithelium. A general down-regulation of ANXA1 mRNA 
expression was observed in tumors. Well-differentiated HNSCC exhibited strong positive ANXA1 expression 
in highly keratinized areas (Fig. 1C), whereas poorly differentiated tumors showed negative ANXA1 expression 
Figure 1. In situ hybridization analysis of ANXA1 mRNA expression (blue, contrasted with nuclear red stain) 
in normal epithelia (A), epithelial dysplasia (B), well-differentiated HNSCC (C), and poorly differentiated 
HNSCC (D). Magnification 20x (A,C,D), and 10x (B). Normal cells stain for ANXA1 in the superficial stratum, 
differentiated HNSCC exhibit positive mRNA expression in highly keratinized areas, and poorly differentiated 
HNSCC do not stain for ANXA1.
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Figure 2. Immunofluorescence analysis of ANXA1 protein expression in HNSCC. Localization of ANXA1 
protein (green) contrasted with propidium iodide (red) in normal epithelia (A), in epithelial dysplasia (middle 
right, B) and foci of differentiated HNSCC (C), and in poorly differentiated HNSCC (D). ANXA1 expression 
is restricted to the superficial stratus of well-differentiated cells in normal tissue (A) and localized to the 
cytoplasm, plasma membrane and nucleoplasm (excluding the nuclear membrane and nucleolus) of normal 
cells (E). In well-differentiated HNSCC, ANXA1 expression is markedly subdued and further restricted to the 
cornified envelope (C) where it is localized exclusively to the plasma membrane of remaining differentiated cells 
(F). ANXA1 expression is completely lost in poorly differentiated HNSCC (D). Scale bar 25 µm (A–D), and 
5 µm (E,F).
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(Fig. 1D). Identical results were obtained by immunofluorescence analysis of ANXA1 protein (Fig. 2A–F), 
demonstrating that ANXA1 down-regulation in HNSCC occurs at the transcriptional level.
ANXA1 mRNA expression inversely correlated with miR-196a and miR-196b levels in HNSCC 
tissue specimens. miR-196a and miR-196b expression levels were analyzed using Taqman miRNA assays in 
11 paired HNSCC tissue samples and patient-matched normal epithelia. Quantitative analysis of miR-196a and 
miR-196b expression showed increased levels of miR-196a and miR-196b in all tumors compared to normal epi-
thelia from non-oncologic patients (Fig. 3A and B). Increased miR-196a and miR-196b levels were also detected 
in three patient-matched normal epithelia. Concomitantly, ANXA1 mRNA levels were significantly reduced 
in the tumor samples compared to paired normal epithelia (Fig. 3C). Consequently, the inverse correlation of 
ANXA1 mRNA levels with both miR-196a and miR-196b levels supports a role of miR-196a/b in the regulation 
of ANXA1 expression in HNSCC.
ANXA1 is a direct target of both miR-196a and miR-196b in HNSCC-derived cell lines. We ver-
ified whether miR-196a and miR-196b regulated the endogenous expression of ANXA1 in HNSCC-derived cell 
lines. Transient transfection with specific pre-miR precursors pre-miR196a and pre-miR196b led to a robust 
induction of mature miR-196a and miR-196b levels (Fig. 4A and B). This was consistently accompanied by a 
significant inhibition of ANXA1 mRNA levels in both SCC42B and FaDu cells, while ANXA2 levels remained 
unaffected by pre-miR transfection (Figure 4C and D). ANXA1 protein expression was also down-regulated upon 
miR-196a and miR-196b overexpression in HNSCC cells both the full-length ANXA1 protein (37 kDa) and the 
cleaved form (33 kDa) (Fig. 4E and F).
Consistent with these findings, we observed that luciferase reporter carrying ANXA1 3′-UTR region was 
sensitive to miR-196a and miR-196b ectopic expression (Fig. 5A). Thus, transfection with pre-mir196a and 
pre-mir196b led to a significant repression (approx. 50%) in all three HNSCC cell lines, while this effect was 
reverted by transfection with specific miR-196a and miR-196b inhibitors (Fig. 5A). In contrast, mutations of a 
miR-196a/b complementary site within ANXA1 3′-UTR prevented miR-196a/b-dependent repression (Fig. 5B). 
These results demonstrate that both miR-196a and miR-196b inhibited ANXA1 expression by its specific binding 
to the 3′-UTR region of ANXA1 mRNA. These data corroborate similar studies affirming that ANXA1 is a direct 
binding target of miR-196a15, 22, 23 and, more importantly, provide the first experimental evidence to prove that 
ANXA1 is a direct target of miR-196b.
Analysis of ANXA1 promoter activity in HNSCC-derived cell lines. We next assessed the ANXA1 
promoter activity in HNSCC cells using a series of deletion constructs from the 5′ ANXA1 promoter region 
subcloned into the luciferase reporter plasmid pGL3-Basic. Figure 6 shows a schematic representation of the 
5′ promoter fragments, including bioinformatic prediction of transcription factor binding sites in the ANXA1 
promoter sequence. The 5′ UTR ANXA1 constructs controlling the expression of firefly luciferase were tran-
siently transfected together with a control Renilla luciferase plasmid into three different HNSCC-derived cell lines 
SCC38, SCC42B and FaDu.
The activity of A1H-1 promoter fragment was robustly increased 5- to 15-fold in all three HNSCC cell lines 
compared to the pGL3-basic empty vector (Fig. 6). Promoter activity slightly decreased in all HNSCC cells 
when the −911/−396 region was deleted (A1H-3). Luciferase activity was further increased by deletion of the 
−396/−172 region (Ax1.2 and Ax1.3) in all three HNSCC cell lines, which suggested the existence of repressor 
elements within this region. Deletion of the −172/−95 sequence (A1H-5) containing the putative p53 binding 
Figure 3. Analysis of miR-196a and miR-196b expression and ANXA1 mRNA levels in HNSCC tissue 
specimens. (A) miR-196a and (B) miR-196b expression levels were quantified by RT-qPCR in 11 fresh primary 
tumors (T) and patient-matched normal epithelia (N). Data were normalized to RNU48 levels, and relative to 
the normal mucosa from non-oncologic patients. (C) ANXA1 mRNA levels were quantified by RT-qPCR and 
data normalized to RPL19 levels. p-values obtained from the Wilcoxon test provided statistical confirmation of 
the significant changes.
www.nature.com/scientificreports/
5SCIENtIFIC RepoRts | 7: 6790 | DOI:10.1038/s41598-017-07169-w
Figure 4.  miR-196a and miR-196b specifically targeted ANXA1 expression in HNSCC-derived cell lines. 
miR-196a and miR-196b expression levels were quantified by RT-qPCR in SCC42B (A) and FaDu (B) cells 
transfected with either premiR-196a, premiR-196b or non-targeting control. Data were normalized to RNU48 
levels and relative to control-transfected cells. mRNA expression levels of ANXA1 and ANXA2 were measured 
by qRT-PCR in SCC42B (C), and FaDu (D) after 72 h transfection with either premiR-196a, premiR-196b 
or non-targeting control. Data were normalized to RPL19 levels and relative to control-transfected cells. 
The graphs represent the mean ± SD, calculated from at least three independent experiments performed in 
triplicate. ANXA1 protein expression was analyzed by Western blot in SCC42B (E) and FaDu (F) cells after 
72 h transfection with either premiR-196a, premiR-196b or non-targeting control. The graphs represent the 
mean ± SD, calculated from at least three independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 by 
Student t-test.
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site consistently and significantly decreased promoter activity in HNSCC cells. In addition, removal of −95/−38 
sequence (A1H-6) containing a CCAAT box yielded to a further reduction in luciferase activity. According to 
these data, the −172/−38 region containing binding sites for p53 and AP1 and the CCAAT proximal box appear 
to be involved in the transcriptional regulation of ANXA1 expression in HNSCC cells.
Discussion
Complex regulatory mechanisms pose a formidable challenge for deciphering gene expression patterns controlled 
by protein transcription factors, non-coding RNAs and their structural modifications at the post-transcriptional 
and epigenetic levels. A knowledge of the network components involved and their specific contribution to indi-
vidual features of different cancers is a long-term therapeutic goal. We focused on the well-documented loss of 
ANXA1 protein expression in HNSCC14, 15, 24 by visualizing the changes using immunofluorescence microscopy. 
This technique vividly highlighted the progressive reduction from normal epithelia (including their nuclei) to 
precancerous lesions and ultimately to major loss in poorly differentiated tumors (Fig. 2). Detailed images of 
annexin A1 mRNA expression from in situ hybridization (Fig. 1) coincided with these protein changes support-
ing the hypothesis of a transcription-mediated mechanism. Only one previous microscopic study has demon-
strated the concomitant changes in annexin A1 mRNA and protein levels in esophageal SCC24 and our results 
Figure 5. ANXA1 is directly targeted by both miR-196a and miR-196b in HNSCC cells. The constructs psi-
CHECK-2-ANXA1–3′UTR-wt (A) and psi-CHECK-2-ANXA1–3′UTR-mut (B) were co-transfected with 
the indicated specific premiR precursors and miRNA inhibitors into SCC38, SCC42B, and FaDu cells. Renilla 
luciferase activity under the control of ANXA1 3′-UTR was measured and normalized to firefly luciferase, 
relative to control-transfected cells. The graphs represent the mean percentage ± SD, calculated from at least three 
independent experiments performed in quadruplicate. *p < 0.05, **p < 0.01 and ***p < 0.001 by Student t-test.
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were complemented by RT-qPCR analysis of mRNA levels (Fig. 3) in accordance with previous studies25, 26. The 
earlier discovery that miR-196a specifically inhibited Anxa1 mRNA translation by directly hybridizing to its 
3′untranslated region argued for a post-transcriptional mechanism of mRNA destabilization in ESCC15, but this 
alone would not account for the eventual, complete loss of Anxa1 nuclear mRNA observed here. Since it has been 
amply demonstrated that ANXA1 is a functional target of miR-196a in various cancers including HNSCC15, 25, 26, 
it remained necessary to determine the specificity and causal relationship between annexin A1 mRNA and pro-
tein levels with miR-196a and miR-196b expression.
The prediction by TargetScan20 that mature miR-196a1, a2 and b were candidates for binding Anxa1 3′UTR 
via sequence hybridization could conceivably account for the RNA degradation and consequent reduction in 
translation to ANXA1. However, both ANXA1 and miR-196 also target other genes including transcription fac-
tors that could modify their respective promoters to affect transcriptional activity. Thus, this inverse relationship 
is specific but not unique and the qualitative and quantitative changes may vary between tissues and cancer 
types9–18. The comparison of paired HNSCC tissue samples and patient-matched normal mucosa pointed to a 
fundamental regulatory control of ANXA1 by miR-196a/b in HNSCC, while in vitro studies established specific-
ity for ANXA1, leaving ANXA2 unchanged, and the reproducibility in different cell types (Fig. 4). Even though 
the differences in ANXA1 protein levels following pre-miR196a overexpression were marginal, pre-miR196b 
overexpression consistently led to a significant reduction of ANXA1 expression at both mRNA and protein levels 
Figure 6. Deletion mapping of the promoter activity in the 5′-UTR sequence of ANXA1 gene. (A) Schematic 
representation of the different ANXA1 promoter fragments used in luciferase activity assays. The predicted 
binding sites for transcription factors relative to the transcription start site (TSS, +1) are also mapped. Promoter 
construct fragments of the proximal regulatory region (−1000 to +500 bp) of the human Annexin A1 gene 
(ANXA1), shown schematically in the six lower bars, were utilized in luciferase assays. The transcription start 
site (TSS) is marked by an arrow and other key elements (TATA-BP, CCAAT-box, p53, ForkHead/FOX) have 
been confirmed by high-throughput ChIP Seq studies (27, UCSC genome browser). The BC200 element25 
may be a ncRNA with a role in squamous cell cancers44. Binding sites for other putative transcription factors 
were those predicted with highest confidence (>90%) by MatInspector (Genomatix). (B) Promoter activity 
of the A1H-1 to A1H-6 constructs in three different HNSCC-derived cell lines (SCC38, SCC42B and FaDu) 
measured with dual luciferase assays 48 h after transfection. Luciferase (firefly) activity was normalized to 
Renilla luciferase. The graphs represent the mean ± SD, calculated from at least three independent experiments 
performed in quadruplicate. *p < 0.05, **p < 0.01 and ***p < 0.001 by Student t-test.
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in both full-length (37 kDa) and cleaved form (33 kDa) in the two different HNSCC cell lines tested. In addi-
tion, down-regulation of ANXA1 protein was accompanied by a concomitant reduction in mRNA levels upon 
pre-miR196a and pre-miR196b overexpression. Subsequent direct analysis of various cell types (Fig. 5) provided 
further evidence that the Anxa1 3′untranslated region is a direct interaction target of miR-196a/b. This does not 
exclude the targeting of other gene products with a potential role in the transcriptional repression of ANXA1 
promoter activity and independent effects on the cancer phenotype. The inverse regulation between ANXA1 
and miR-196 could also be mediated by induced changes in distinct miRNAs and relevant transcription factors. 
It is particularly noteworthy that ANXA1 and miR-196a have been shown to coregulate each other in a negative 
feedback loop in breast cancer through c-myc and NFkappaB11 and that ANXA1 regulation of other microRNAs 
and transcription factors could further contribute to the accompanying changes in NFkappaB and miR-19610.
An alternative scenario for esophageal SCC was recently presented26 in which ANXA1 induction of Snail and 
reduction of both E-cadherin and miR-196a reproduced the pathogenic phenotype, while miR-196a transfection 
had the opposite effect. miR-196b is a post-transcriptional inhibitor of the GATA transcription factor27, which 
interacts with ANXA128 possibly by binding to its promoter (see Fig. 6a). Since mutations that affect the binding 
site interactions of miRNAs and their target genes can be relevant to tumorigenesis, our inclusion of the nucle-
otide variant miR-196b, located on a different chromosome than miR-196a, demonstrated qualitatively similar 
effects on ANXA1 and, by inference, binding affinity. The mechanisms of miR-196a/b transcriptional regulation 
and the possible roles of their respective HOX gene clusters as well as ANXA1 merit further investigation10, 11. The 
study of ANXA1 promoter constructs in HNSCC-derived cell lines also established the presence of active regula-
tory sites in the 5′ non-transcribed region (−172 to −38 bp) (Fig. 6) with potential binding sites for transcription 
factors such as FOX, NFAT, p53, AP1, Sp1, CCAT, CEBP, TAT, GATA, corroborating and extending previous 
studies29, 30. Transcription factor binding to the p53 binding site or the CCAAT proximal box influenced by his-
tone acetylation30 could also affect ANXA1 transcriptional expression and possible tumor suppressor activity.
Our combined results showed that ANXA1 expression is markedly suppressed in all primary HNSCC tumors 
compared to the corresponding normal epithelia at the levels of both mRNA and protein. This coincided with an 
inverse regulatory role by miR-196a/b and ANXA1, presumably via direct effects on mRNA stability and protein 
translation, but conceivably also through secondary mediators of transcriptional control such as trans-acting 
protein factors. The question of sequential order thus becomes important to establish whether ANXA1 or miR-
196a/b is primarily responsible for either initiating or promoting the pathogenic phenotype. Although we find 
that upstream changes in miR-196 can alter annexin A1 mRNA levels and hence protein levels, the idea that 
miR-196 is acting as regulator and ANXA1 as effector is overly simplistic in view of evidence for accompanying 
changes in many other signaling factors. Clearly, miR-196 and ANXA1 actions are part of a more complex regula-
tory network. Numerous other parameters such as transcription factors and miRNAs mentioned above may also 
be influenced secondarily by post-transcriptional modifications and epigenetic alterations and elucidation of the 
entire chain of events awaits more detailed scrutiny.
It has become apparent that miR-196a/b are altered in many forms of cancer15, 31–34 and are considered to 
have an oncogenic profile25, 35–39. The downstream inhibition of ANXA1 expression in turn has phenotypic con-
sequences consistent with many of the known actions of ANXA1, including cell differentiation, proliferation, 
migration, apoptosis, immunosuppression and even vascular changes1–5, 40. The observations that miR-196 over-
expression and annexin A1 underexpression are under both transcriptional and translational control would seem 
to offer a pathogenic mechanism in HNSCC. However, the opposing qualitative changes are dependent on the 
cancer type being considered4, 18, 22 and other effectors must contribute to the phenotypic consequences. The 
bidirectional regulation of miR-196a/b and ANXA1 could even represent a compensatory, homeostatic response 
to cancer progression31 influenced by the specific tumor microenvironment. Additional factors responsible for 
changes in miR-196a/b and ANXA1 thus merit further investigation to delineate the network of cellular processes 
responsible for initiating, promoting or suppressing oncogenesis in HNSCC16, 18. Our tentative conclusion is that 
ANXA1 and miR-196 changes are more closely related to the pathogenic features rather than the etiology of 
HNSCC and that correction of their misregulation could ameliorate conditions through cancer stem cell differ-
entiation, its associated markers and decreased metastatic potential. Bioinformatics based approaches41 utilizing 
resources such as the Human miRNA Disease Database (HMDD) associations (http://www.cuilab.cn/hmdd) 
should help to gain further insight into the molecular mechanisms of HNSCC.
Methods
Patients and Tissue Specimens. Surgical tissue specimens (fresh frozen) from 11 patients with HNSCC 
who underwent resection of their tumors at the Hospital Universitario Central de Asturias between 2000 and 
2002 were collected, in accordance to approved institutional review board guidelines. The clinicopathologic char-
acteristics of these patients are shown in Supplementary Table S1. Patient-matched normal adjacent epithelia were 
also collected from all the patients. In addition, normal epithelia from non-oncologic patients without exposure 
to tobacco carcinogens (i.e. childhood tonsillectomy) were collected and used as healthy controls.
Representative tissue sections from HNSCC (FFPE) were obtained from archival, paraffin-embedded blocks 
from the Hospital Universitario Central de Asturias, in accordance to approved institutional review board 
guidelines. All experimental protocols were approved by the Institutional Ethics Committee of the Hospital 
Universitario Central de Asturias and by the Regional CEIC from Principado de Asturias. Informed consent was 
obtained from all patients. All patients had a single primary tumor (in the larynx or pharynx), microscopically 
clear surgical margins and received no treatment prior to surgery. In addition, FFPE tissue sections from patients 
with a diagnosis of laryngeal precancerous lesion (dysplasia) were obtained from the Hospital pathology archives. 
All the tissue sections selected also included normal adjacent epithelia as internal control.
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In situ hybridization. In situ hybridization was carried out following the procedure that we previously 
described42. The formalin-fixed paraffin-embedded tissues were cut into 4 µm sections onto Superfrost plus glass 
slides (Menzel-Glaser). The sections were deparaffinized, hydrated and rinsed in PBS. After pre-treatment with 
proteinase K (20 µg/ml) for 7.5 min at room temperature, the sections were rinsed in PBS, refixed with 3.7% 
paraformaldehyde and rinsed again in PBS. The slides were incubated with the labeled antisense Anxa1 probes 
in the hybridization mix for 12 h at 60 °C. Subsequently, the sections were washed in 5x SSC, treated with 2x SSC 
containing 25% formamide, followed by sequential washes in 2x SCC, 0.2x SCC and rinsed in PBS-0.1% Tween 
20 (PBT).
The Anxa1 probe comprises the full coding cDNA sequence obtained by RT-PCR from human placenta RNA 
and subcloned in pBSK(SK+ ). Digoxigenin-labeled antisense and sense riboprobes were prepared by using this 
plasmid and DIG-UTP for in vitro transcription reactions, with T3 and T7 RNA polymerases using the DIG-RNA 
labeling kit T3/T7 (Roche). For the hybrid detection of digoxigenin antibody, the samples were pre-blocked with 
5% sheep serum in PBS-T for 30 min and then incubated with anti-digoxigenin antibody conjugated with alkaline 
phosphatase (Roche) diluted 1:2000 in PBT containing 5% sheep serum overnight at 4 °C and visualized with 
NBT-system (Roche). The tissues were counterstained with nuclear red for 5 min as the final step. Following 
staining, the slides were dehydrated through graded alcohols and mounted with the coverslip. The counterstained 
sections were evaluated with a Zeiss Axioscope 2 Plus microscope, photographed with Zeiss Axio-Cam HRC 
camera, and images were rendered by Adobe Photoshop software.
Immunofluorescence. The formalin-fixed paraffin-embedded tissues were cut into 4 µm sections onto 
Superfrost plus glass slides (Menzel-Glaser). The sections were deparaffinized with standard xylene and hydrated 
through graded alcohols into water. While hydrating the deparaffinized sections in graded alcohol, the slides were 
immersed for 1 h in 70% ethanol supplemented with 0.25% NH3, and rehydration was resumed by immersion 
in 50% ethanol for 10 min and rinsed in PBS. Before immunostaining, the samples were sequentially incubated 
in 0.5% Triton X-100 in PBS for 30 min, 0.1 M glycine in PBS for 15 min, and blocked with 0.1% bovine serum 
albumin in PBS for 30 min. They were rinsed in PBS-0.05% Tween 20, incubated for 2 h with mouse anti-Annexin 
A1 monoclonal antibody (BD Transduction Laboratories) diluted in PBS, washed in PBS containing 0.05% Tween 
20, and incubated for 45 min with the appropriate secondary antibodies conjugated to fluorescein isothiocy-
anate (FITC) (Jackson Immunoresearch Laboratories, West Grove, PA). The samples were counterstained with 
Propidium Iodide (PI) for the cytochemical demonstration of nucleic acids. Finally, the coverslips were mounted 
in VectaShield (Vector Laboratories, Peterborough, United Kingdom) and sealed with nail polish. Confocal 
microscopy was performed with a Leyca TSC-SP2-AOBS laser confocal microscope, using wavelengths of 488 nm 
(for FITC) and 543 nm (for IP). Each channel was recorded independently, and pseudocolor images were gener-
ated and superimposed. Images were handled by the Adobe Photoshop 7.0 software.
miRNA expression analysis. Total RNA (including miRNA) was extracted from fresh frozen tissue and/
or cultured cells using Trizol (Invitrogen Life Technologies). The relative levels of miR-196a and miR-196b were 
determined by two-step RT-PCR using miRNA-specific primers and probes according to the Taqman miRNA 
Assay protocol (Applied Biosystems) on a StepOnePlus Real-Time PCR System (Applied Biosystems). Reactions 
were run in triplicate, using RNU48 as control. The relative miRNA expression was calculated using the 2−ΔΔCT 
method and the data were normalized to RNU48 levels and relative to the normal mucosa from non-oncologic 
patients.
Cell culture. The HNSCC-derived cell lines SCC38 and SCC42B were kindly provided by Dr. R. Grenman 
(Department of Otolaryngology, University Central Hospital, Turku, Finland)43. FaDu cells were purchased to the 
ATCC. Cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 200 mg/
ml streptomycin, 2 mmol/l L-glutamine, 20 mmol/l HEPES (pH 7.3) and 100 mmol/l non-essential amino acids.
Transfections with pre-miR miRNA precursors. Ambion Pre-miR miRNA Precursors AM17100 
hsa-miR-196a (#PM10068) and hsa-miR-196b (#PM12946) were purchased to Thermo Fisher Scientific and 
siGLO RISC-Free™ was used as non-targeting control (Thermo Scientific Dharmacon).
HNSCC cells were seeded in 6-well plates at a density of 60,000 cells. The next day, cells were transfected with 
100 nM of either pre-miR196a or pre-miR196b or a non-targeting control using Lipofectamine 2000 Transfection 
Reagent (Invitrogen Life Technologies), according to the manufacturer’s protocol. miRNA expression or mRNA 
gene expression was tested by real-time RT-PCR at 72 h post-transfection.
RNA extraction and real-time RT-PCR. Total RNA was extracted from HNSCC cells using Trizol rea-
gent (Invitrogen Life Technologies), and cDNA synthesized with Superscript II RT-PCR System (Invitrogen Life 
Technologies), according to manufacturer’s protocols. Gene expression was analyzed by Real-time PCR using the 
StepOnePlus Real-Time PCR System (Applied Biosystems) following Applied Biosystems’ SYBR Green Master 
Mix protocol. Reactions were carried out using the primers detailed in Supplementary Table S2. The constitutively 
expressed RPL19 ribosomal coding gene was used as endogenous control. The relative mRNA expression was 
calculated using the 2−ΔΔCT method and the data were expressed as the fold-change normalized to RPL19 mRNA 
levels and relative to normal epithelia from oncologic patients (or control-transfected cells).
Western blot analysis. Proteins were extracted from HNSCC cells transfected with either pre-miR196a, 
pre-miR196b or a non-targeting control at 72 h post-transfection using lysis buffer (R&D Systems). Protein lysates 
were resolved by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and transferred subsequently to nitrocel-
lulose membranes (Amersham Protran, GE Healthcare).
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The membranes were blocked for 1 h with Odyssey blocking buffer and incubated overnight with rabbit pol-
yclonal ANXA1 (at 1:1,000 dilution) raised in our laboratory against the human recombinant protein and the 
anti-β-actin (dilution 1:10,000 for 1 h; from Sigma Aldrich # AC15). The IRDye Infrared Fluorescent second-
ary antibodies Goat anti-Rabbit IRDye 800CW and Goat anti-Mouse IRDye 680RD were used for detection. 
Membranes were scanned with the Odyssey Fc Dual-Mode Imaging System (LI-COR Biosciences) using the red 
(700 nm) and green (800 nm) channels.
Luciferase reporter assays. Dr. Jacques Huot kindly provided the constructs psi-CHECK-2-ANXA1–
3′UTR-wt containing Renilla luciferase under the control of ANXA1 3′-UTR and firefly luciferase as a control and 
psiCHECK-2-ANXA1–3′UTR-mut generated by directed mutagenesis in the predicted miR196 binding site22.
HNSCC cells were seeded into 96-well plates in antibiotic-free medium at a density of 4,000 cells per well 
(6,000 cells for SCC38). The next day, cells were transfected with psi-CHECK-2-ANXA1–3′UTR-wild type 
or psiCHECK-2-ANXA1–3′UTR-mutated (20 ng/well) together with pre-miR196a or pre-miR196b or a 
non-targeting control (100 nM) or miRNA inhibitors using Lipofectamine 2000. Cells were lysed 48 h after trans-
fection and luciferase activity evaluated using Dual-Luciferase Reporter Assay System following manufacturer’s 
protocol (Promega). Renilla luciferase activity which is under the control 3′-UTR insert was evaluated and firefly 
luciferase was measured as a loading control in each condition using a Synergy HT Multi-Mode Microplate 
Reader (Biotek).
For ANXA1 promoter analysis, several plasmid constructs, containing different fragments of the promoter 
region of ANXA1 gene, were obtained. The construct A1H-1 (−911/+266) was made by PCR amplification with 
specific oligonucleotide primers and a 3633 bp XbaI subclone spanning from −2206 to +1427 positions44 as tem-
plate. The resulting 1177 bp PCR product was blunt ended and subcloned into the SmaI site of pBSK plasmid and 
sequenced to determine orientation. From this plasmid a fragment excised with StuI and Hind3 was purified and 
ligated into the SmaI and HindIII sites of pGL3 Basic vector (Promega). Similarly for the A1H-3 (−396/+266), 
a previous genomic subclone was generated in pBSK vector containing the desired fragment spaning from the 
EcoRI site at position −396 to +266 which was subsequently excised also with SmaI and HindIII, purified and 
ligated into the SmaI and HindIII sites of pGL3 Basic vector (Promega). Other constructs Ax1.2 (−318/+266) and 
Ax1.3 (−172/+266) were kindly provided by Dr. SE Moss29, and A1H-5 (−95/+266) and A1H-6 (−38/+266) by 
Dr. MA Lizarbe30.
24 h before transfection, HNSCC cells were seeded into 96-well plates in complete media at a density of 
4,000 cells per well (6,000 cells for SCC38). Cells were transfected using FuGENE 6 (Promega) with each of the 
indicated ANXA1 reporter constructs (30 ng/well) or the empty vector pGL3-Luc (Promega) and the pRL-TK 
(Promega) control plasmid (10 ng). The pSG5 empty vector was used to normalize the total DNA amount to 50 ng 
per well. After 48 h transfection, cells were lysed and extracts assayed for luciferase activity using Dual-Luciferase 
Reporter Assay System (Promega). Firefly luciferase activity was normalized to Renilla activity.
Statistical analysis. The data are presented as the mean ± standard deviation (SD), and compared using 
Student’s t-test. Wilcoxon test was used for paired samples. Statistical analysis was performed using GraphPad 
Prism version 6.0 (Graphpad Software Inc, La Jolla, CA, USA). p values less than 0.05 were considered statistically 
significant (p < 0.05, *; p < 0.01, **; p < 0.005, ***).
References
 1. Gerke, V., Creutz, C. E. & Moss, S. E. Annexins: linking Ca2+ signalling to membrane dynamics. Nature Rev Molec Cell Biol. 6, 
449–461 (2005).
 2. Gobbetti, T. & Cooray, S. N. Annexin A1 and resolution of inflammation: tissue repairing properties and signalling signature. Biol 
Chem. 397, 981–993 (2016).
 3. Gastardelo, T. S. et al. Inflammation and cancer: role of annexin A1 and FPR2/ALX in proliferation and metastasis in human 
laryngeal squamous cell carcinoma. PLoS One 9, e111317 (2014).
 4. Guo, C., Liu, S. & Ming-Zhong Sun, M. Z. Potential role of Anxa1 in cancer. Future Oncol. 9, 1773–1793 (2013).
 5. Skouteris, G. G. & Schröder, C. H. The hepatocyte growth factor receptor kinase-mediated phosphorylation of lipocortin-1 
transduces the proliferating signal of the hepatocyte growth factor. J Biol Chem. 271, 27266–27273 (1996).
 6. Solito, E. et al. Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human 
folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, 
phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology 144, 1164–1174 (2003).
 7. Alldridge, L. C. & Bryant, C. E. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 
expression through sustained activation of the ERK1/2 MAPK signal. Exp Cell Res. 290, 93–107 (2003).
 8. Hippo, Y. et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or 
lymph nodes. Cancer Res. 61, 889–895 (2001).
 9. Masaki, T. et al. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 24, 
72–81 (1996).
 10. Anbalagan, D. et al. Annexin-A1 regulates microRNA-26b* and microRNA-562 to directly target NF-kappaB and angiogenesis in 
breast cancer cells. PLoS One 9, e114507 (2014).
 11. Yuan, Y. et al. ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer 
proliferation. Oncotarget 7, 27007–27020 (2016).
 12. Kang, J. S. et al. Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. 
Clin Cancer Res. 8, 117–123 (2002).
 13. Paweletz, C. P. et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 
60, 6293–6297 (2000).
 14. Garcia Pedrero, J. M. et al. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. 
Am J Pathol. 164, 73–79 (2004).
 15. Luthra, R. et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. 
Oncogene 27, 6667–6678 (2008).
www.nature.com/scientificreports/
1 1SCIENtIFIC RepoRts | 7: 6790 | DOI:10.1038/s41598-017-07169-w
 16. Sethi, N., Wright, A., Wood, H. & Rabbitts, P. MicroRNAs and head and neck cancer: reviewing the first decade of research. Eur J 
Cancer 50, 2619–2635 (2014).
 17. Masood, Y., Kqueen, C. Y. & Rajadurai, P. Role of miRNA in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 
15, 183–197 (2015).
 18. Koshizuka, K. et al. The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma. J Hum 
Genet. 62, 3–13 (2017).
 19. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 
42, D68–73, http://www.mirbase.org/ (2014).
 20. Agarwal, V., Bell, G. W., Nam, J. W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4, http://
www.targetscan.org/ (2015).
 21. Stadler, P. F. & Tanzer, A. Molecular evolution of a microRNA cluster. J Mol Biol. 339, 327–335 (2004).
 22. Pin, A. L. et al. Annexin-1-mediated endothelial cell migration and angiogenesis are regulated by vascular endothelial growth factor 
(VEGF)-induced inhibition of miR-196a expression. J Biol Chem. 287, 30541–30551 (2012).
 23. Darda, L. et al. The role of HOXB9 and miR-196a in head and neck squamous cell carcinoma. PLoS ONE 10, e0122285 (2015).
 24. Hu, N. et al. Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin Cancer Res. 10, 
6013–6022 (2004).
 25. Suh, Y. E. et al. MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and 
enhancing radioresistance. Int J Cancer 137, 1021–1034 (2015).
 26. Han, G. et al. Effect of Annexin A1 gene on the proliferation and invasion of esophageal squamous cell carcinoma cells and its 
regulatory mechanisms. Int J Mol Med. 39, 357–363 (2017).
 27. Fantini, S., Salsi, V., Reggiani, L., Maiorana, A. & Zappavigna, V. The miR-196b miRNA inhibits the GATA6 intestinal transcription 
factor and is upregulated in colon cancer patients. Oncotarget 8, 4747–4759 (2017).
 28. Huang, P., Zhou, Y., Liu, Z. & Zhang, P. Interaction between ANXA1 and GATA-3 in Immunosuppression of CD4+ T Cells. 
Mediators Inflamm. 2016, 1701059 (2016).
 29. Donnelly, S. R. & Moss, S. E. Functional analysis of the human annexin I and VI gene promoters. Biochem J. 332, 681–687 (1998).
 30. Lecona, E. et al. Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and 
p38 mitogen-activated protein kinase. Mol Cell Biol. 28, 4665–4674 (2008).
 31. Chen, C., Zhang, Y., Zhang, L., Weakley, S. M. & Yao, Q. MicroRNA-196: critical roles and clinical applications in development and 
cancer. J Cell Mol Med. 15, 14–23 (2011).
 32. Lu, Y. C. et al. miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers. J Cancer 7, 650–655 (2016).
 33. Mueller, D. W. & Bosserhoff, A. K. MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int 
J Cancer 129, 1064 (2011).
 34. Severino, P. et al. MicroRNA expression profile in head and neck cancer: HOX-cluster embedded microRNA-196a and microRNA-
10b dysregulation implicated in cell proliferation. BMC Cancer 13, 533 (2013).
 35. Tsai, K. W. et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer 
514, 394–401 (2012).
 36. Lim, J. Y. et al. Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. World J 
Gastroenterol 1941, 7078–7088 (2013).
 37. Lu, Y. C. et al. OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling 
pathway. Mol Cancer 131, 218 (2014).
 38. Ge, J., Chen, Z., Li, R., Lu, T. & Xiao, G. Upregulation of microRNA-196a and microRNA-196b cooperatively correlate with 
aggressive progression and unfavorable prognosis in patients with colorectal cancer. Cancer Cell Int. 141, 128 (2014).
 39. Mo, J. S. et al. MicroRNA 196B regulates FAS-mediated apoptosis in colorectal cancer cells. Oncotarget 65, 2843–2855 (2015).
 40. Leoni, G. & Nusrat, A. Annexin A1: shifting the balance towards resolution and repair. Biol Chem. 397, 971–979 (2016).
 41. You, Z.-H. et al. PBMDA: A novel and effective path-based computational model for miRNA-disease association prediction. PLoS 
Comput Biol 13, e1005455 (2017).
 42. Pena-Alonso, E. et al. Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck 
squamous cell carcinoma. Cancer Lett. 263, 89–98 (2008).
 43. Lansford, C. D. et al. Head and neck cancers in Human Cell Culture (eds Masters, J.R.W. & Palsson, B.) 185–255 (Kluwer Academic 
Press, 1999).
 44. Morgan, R. O. & Fernandez, M. P. A BC200-derived element and Z-DNA as structural markers in annexin I genes: relevance to Alu 
evolution and annexin tetrad formation. J Mol Evol. 41, 979–985 (1995).
Acknowledgements
We thank Prof. Moss and Dr. Lizarbe for kindly providing 5′ ANXA1 constructs and Dr. Huot for the constructs 
psi-CHECK-2-ANXA1–3′UTR-wt/-mut. This study was supported by grants from the Plan Nacional de I + D + I 
2013–2016 ISCIII (CP13/00013 and PI13/00259 to JMGP), RD12/0036/0015 of Red Temática de Investigación 
Cooperativa en Cáncer (RTICC), PI16/00280 and CIBERONC (CB16/12/00390) Spain, the Principado de 
Asturias (SV-PA-13-ECOEMP-69 and GRUPIN14-097 (MPF and ROM) and the FEDER Funding Program from 
the European Union. SAT and MAV were recipients of fellowships from ISCIII (FI12/00415 and CD13/00157, 
respectively).
Author Contributions
S.A.T., S.T.M., M.A.V. and E.P.A. conceived and carried out experiments; J.P.R., R.O.M., R.G.D. and C.S. analysed 
data; J.M.G.P. and M.P.F. conceived experiments, analysed data and was involved in writing the manuscript. All 
authors approved the final version of the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-07169-w
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 2SCIENtIFIC RepoRts | 7: 6790 | DOI:10.1038/s41598-017-07169-w
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
